[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449332":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":40,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving Somavert",null,[12],"Drug: Somavert",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Somavert","As provided in real world practice",[9],[20],{"name":21,"affiliation":5,"role":22},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[29],{"facility":5,"status":30,"city":31,"state":10,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"RECRUITING","Seoul","01037","South Korea",{"type":35,"coordinates":36},"Point",[37,38],126.9784,37.566,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100449332",false,"NCT05131100","Korean Regulatory Post Marketing Surveillance for Somavert","Korean Post-marketing Surveillance for Somavert","Inclusion Criteria:\n\nAll patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.\n\nExclusion Criteria:\n\nPatients who are contraindicated for Somavert","ALL","18 Years",{"count":51,"type":52},100,"ESTIMATED","OBSERVATIONAL","Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)",[56],"Acromegaly",[58],"acromegaly, Somavert, Post-Marketing Surveillance","2025-07-02",{"date":61,"type":62},"2025-07-04","ACTUAL",{"date":64,"type":62},"2022-07-13",{"date":66,"type":52},"2026-09-15",{"name":5,"class":6},1]